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OBJECTIVES This study evaluated the effect of the glycoprotein IIb/IIIa (GPIIb/IIIa) antagonist abciximab
on myocardial hypoperfusion during percutaneous transluminal rotational atherectomy
(PTRA).
BACKGROUND PTRA may cause transient ischemia and periprocedural myocardial injury. A platelet-
dependent risk of non-Q-wave infarctions after directional atherectomy has been described.
The role of platelets for the incidence and severity of myocardial hypoperfusion during PTRA
is unknown.
METHODS Seventy-five consecutive patients with complex lesions were studied using resting Tc-99m
sestamibi single-photon emission computed tomography prior to PTRA, during, and 2 days
after the procedure. The last 30 patients received periprocedural abciximab (group A) and
their results were compared to the remaining 45 patients (group B). For semiquantitative
analysis, myocardial perfusion in 24 left ventricular regions was expressed as percentage of
maximal sestamibi uptake.
RESULTS Baseline characteristics did not differ between the groups. Transient perfusion defects were
observed in 39/45 (87%) patients of group B, but only in 10/30 (33%) patients of group A
(p , 0.001). Perfusion was significantly reduced during PTRA in 3.3 6 2.5 regions in group
B compared to 1.4 6 2.5 regions in group A (p , 0.01). Perfusion in the region with maximal
reduction during PTRA in groups B and A was 76 6 15% and 76 6 15% at baseline,
decreased to 56 6 16% (p , 0.001) and 67 6 14%, respectively, during PTRA (p , 0.01 A
vs. B), and returned to 76 6 15% and 80 6 13%, respectively, after PTRA. Nine patients in
group B (20%) and two patients in group A (7%) had mild creatine kinase and/or troponin
t elevations (p 5 0.18). Patients with elevated enzymes had larger perfusion defects than did
patients without myocardial injury (4.2 6 2.7 vs. 2.3 6 2.5 regions, p , 0.05).
CONCLUSIONS These data indicate that GPIIb/IIIa blockade reduces incidence, extent and severity of
transient hypoperfusion during PTRA. Thus, platelet aggregation may play an important role
for PTRA-induced hypoperfusion. (J Am Coll Cardiol 1999;33:998–1004) © 1999 by the
American College of Cardiology
Percutaneous transluminal rotational atherectomy (PTRA)
is commonly employed in small coronary arteries, long and
diffuse, calcified and ostial lesions (1–3). Previous experi-
ences in complex and calcified coronary lesions demon-
strated the potential of this technique to remove plaque
material (4). However, transient ischemia during PTRA
and frequent procedure-related non-Q-wave infarctions
have been reported (1–3,5). A scintigraphic approach to
assess the frequency, severity and reversibility of perfusion
abnormalities during PTRA by serial myocardial perfusion
single-photon emission computed tomography (SPECT)
with Tc-99m-sestamibi using the advantage of myocardial
sestamibi kinetics, which allows delayed imaging of
procedure-related hypoperfusion, was recently described by
our laboratory (6).
Blockade of the platelet glycoprotein IIb/IIIa (GPIIb/
IIIa) receptor during directional atherectomy reduces the
incidence of non-Q-wave infarction (7) and reduces creatine
kinase (CK) elevations and clinical complications following
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PTRA (8). Recent in vitro experiments from several groups
have shown that PTRA-induced platelet activation and
aggregation can be inhibited by GPIIb/IIIa blockade (9,10).
These data suggest that myocardial injury following
atherectomy procedures is partially platelet-dependent.
This study sought to evaluate quantitatively the effect of
GPIIb/IIIa receptor blockade by periprocedural administra-
tion of abciximab (Reopro) on myocardial hypoperfusion
during PTRA using serial Tc-99m sestamibi SPECT.
METHODS
Patients. Seventy five consecutive patients scheduled for
PTRA of complex coronary lesions in the presence of stable
angina pectoris symptoms and/or objective signs of ischemia
were prospectively studied. The methodological approach
has been reported previously describing the first 29 patients
(6). The conventional treatment group (group B) consisted
of 45 patients including these 29 patients. After 10 addi-
tional patients had been included in the conventional
treatment group (group B), the following nonselected pa-
tients received peri-interventional treatment with abciximab
(group A, n 5 30), unless contraindications for GPIIb/IIIa
blockade were present, in which case the patients (n 5 6)
were included in group B. The following contraindications
for abciximab administration were considered: cerebrovas-
cular complications within the past two years, neurosurgery
within the past two months, intracranial tumors, known
bleeding diathesis (n 5 1), history of internal bleeding (n 5
3), severe hypertension, thrombocytopenia, vasculitis, dia-
betic or hypertensive retinopathy, severe hepatic or renal
disease, and previous abciximab administration (n 5 2).
The institutional ethical committee approved the study
protocol, and patients gave informed consent.
Rotational atherectomy and angiographic analysis. The
technique of PTRA has been described previously in detail
(1). Incremental burr sizes with steps #0.5 mm achieving an
attempted burr/artery ratio of $0.7 were used. Several slow
burr passages (#30 s) were performed at $165,000 rpm
with sufficient pauses and saline flushing between each
advancement. Burr speed was routinely monitored and
decelerations .5,000 rpm were avoided. Adjunctive percu-
taneous transluminal coronary angioplasty (PTCA) with or
without additional stenting was performed as needed for
optimal angiographic result at the operator’s discretion. In
patients with a lesion of the right coronary artery, a
temporary pacemaker was positioned in the right ventricle
to prevent the effects of atherectomy-induced bradycardia.
Lesion length and severity were off-line digitally quanti-
fied (CAAS, PieMedical, Maastricht, The Netherlands).
The degree of calcification was assessed by visual analysis
using a three-grade scale: severe calcification: readily appar-
ent on single-frame cineangiography; mild calcification:
artery motion required to visualize; no visible calcification
(2).
Procedural success was defined as final diameter stenosis
of less than 50% in the absence of major complications
(death, emergency bypass surgery, and Q-wave myocardial
infarction). A non-Q-wave infarction was defined as eleva-
tion of creatine kinase (CK) more than three times the
upper limit of normal in the absence of pathological
Q-waves. “No flow” was defined as delayed antegrade flow
(TIMI [Thrombolysis in Myocardial Infarction trial] grade
less than 2) in the absence of a clear angiographic explana-
tion of impaired flow (dissection, thrombus, spasm) at or
adjacent to the original lesion.
Periprocedural medication. Preprocedural medication in-
cluded aspirin (100 mg daily) and antianginal drugs (Table
1). All patients were pretreated with ticlopidine (250 mg
twice daily) beginning 1 day before the intervention in
anticipation of a possible stent deployment. In patients in
which no stent was deployed, ticlopidine was discontinued
after the intervention. During the procedure, 10,000 IU of
heparin were administered through the guiding catheter.
Prior to baseline angiography, 0.2 mg nitroglycerin was
injected intracoronarily and repeated during the procedure
at the discretion of the operator to minimize vessel spasm
(Table 1). Except for an intracoronary saline infusion, no
specific treatment was given. Intravenous abciximab was
administered as a bolus (0.25 mg/kg) $10 min prior to
PTRA, followed by an infusion of 10 mg/min for 12 h.
SPECT imaging and analysis. For assessment of regional
myocardial perfusion, SPECT with Tc-99m sestamibi was
performed 1 day before, during PTRA and 2 days after the
procedure as described previously (6). The Tc-99m sesta-
mibi (400 to 450 MBq) was administered intravenously to
the resting and fasting patient. During rotational atherec-
tomy, intravenous Tc-99m-sestamibi was injected immedi-
ately after the last burr passage and intracoronary saline
flushing and retrieval of the burr into the guiding catheter.
Before SPECT imaging, the patient was allowed to have a
light meal to minimize artifacts caused by enteric tracer
uptake. The SPECT imaging and the data acquisition were
performed 60 to 90 min after tracer injection in every study.
Automated semiquantitative image analysis was per-
formed without knowledge of clinical or angiographic data
using a rotating double-head gamma camera with a low-
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energy all-purpose collimator (ROTA II, Siemens, Ger-
many). Transversal slices were reconstructed (Butterworth
filter 5th order, 0.5 cutoff frequency, slice thickness
6.25 mm, matrix 64 3 64) and long and short axis views
were obtained using dedicated software (MaxDelta, Sie-
mens, Germany) and hardware (Micro Vax II, Siemens,
Germany). For semiquantitative analysis the left ventricular
myocardium was divided into 24 regions. Regional myocar-
dial perfusion was expressed as percentage of the region
with the maximal tracer uptake in each individual data set.
Perfusion below 2 SDs of each regional normal mean value,
derived from rest studies in a collective of normal individuals
from our institution, was defined as significantly reduced.
Myocardial enzymes. Blood samples were drawn at base-
line, and 8 h, 16 h and 24 h following the procedure for
determination of total CK, CK-MB (creatine kinase MB
fraction) and cardiac troponin t (TrT). Both CK and
CK-MB were determined using a kinetic method for total CK
and immunoinhibition for CK-MB (11). For quantitative
measurement of TrT an enzyme-linked-immunosorbent assay
was used (12). Creatine kinase was defined as elevated when
.100 U/l with a CK-MB fraction .6%. Troponin t was
defined as elevated when .0.1 ng/ml.
Statistical analysis. Data are mean 6 SD. Differences in
continuous variables were assessed using the Student t test
Table 1. Patient, Lesion and Procedural Characteristics
Group A
(n 5 30)
(abciximab)
Group B
(n 5 45)
(control) p
Patients
Age (yrs) 60 6 11 61 6 9 0.67
Male 23 (77) 32 (71) 0.79
Ejection fraction (%) 64 6 6 62 6 9 0.29
Medication
Nitrates 23 (77) 38 (84) 0.55
Beta-blockers 16 (67) 28 (62) 0.48
Calcium channel antagonists 14 (47) 23 (51) 0.82
Intracoronary Nitrates during PTRA (mg) 0.8 6 0.4 0.7 6 0.4 0.29
Vessel
LAD 13 (43) 20 (44) 1.0
RCA 14 (47) 18 (40) 0.64
LCX 3 (10) 7 (16) 0.73
Previous myocardial infarction (non-Q-wave)
in target vessel territory
13 (43) 19 (42) 1.0
Lesion
Type A 1 (3) 0 0.4
Type B 5 (17) 7 (16) 0.76
Type C 24 (80) 38 (84) 0.76
Length (mm) 27 6 21 28 6 12 0.79
Calcified 9 (30) 14 (33) 1.0
Collaterals 12 (40) 19 (42) 1.0
Procedure
Burr diameter (mm) 2.0 6 0.3 1.9 6 0.2 0.09
Number of burrs 2.2 6 0.7 2.0 6 0.5 0.15
Total burring time (s) 149 6 81 155 6 93 0.77
Number of passages 6.8 6 3.4 7.8 6 4.0 0.27
Mean burring time per passage (s) 22 6 8.0 20 6 4.9 0.18
Adjunctive PTCA 30 (100) 42 (93) 0.27
Adjunctive stent 12 (40) 18 (40) 1.0
Transient dissection, spasm, “no flow” 6 (20) 12 (27) 0.79
Reference diameter (mm) 2.8 6 0.5 2.7 6 0.6 0.45
Diameter stenosis (%) at baseline 71 6 14 69 6 14 0.55
Diameter stenosis (%) after PTRA 51 6 11 49 6 8 0.37
Diameter stenosis (%) after PTCA/stent 29 6 10 32 6 7 0.13
Success 30 (100) 44 (98) 1.0
Reintervention during hospital stay 0 1 (2) 1.0
Numbers in brackets are %.
LAD 5 left anterior descending coronary artery; LCX 5 left circumflex artery; RCA 5 right coronary artery. Lesion types
A–C according to the American Heart Association/American College of Cardiology classification.
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for paired and unpaired samples, and categorical variables
were tested by the Fisher exact test.
RESULTS
Baseline patient, lesion and procedural characteristics.
Baseline and procedural characteristics are presented in
Table 1. For all baseline characteristics and procedural
parameters there was no significant difference between
group A and group B. Lesions were complex (type B and
type C) and long (mean length 28 mm). Approximately
30% of the lesions were calcified and 40% were collateral-
ized. No patient had a previous transmural Q-wave myo-
cardial infarction in the target vessel territory, whereas
approximately 40% of patients in each group had a previous
non-Q-wave infarction. Adjunctive PTCA was performed
in almost all procedures and adjunctive stents were im-
planted in 40% of patients. Clinical success rate was high,
and only one patient in group B required a reintervention
during hospital stay.
Influence of abciximab on myocardial perfusion during
PTRA. Visual analysis of SPECT images revealed tran-
sient perfusion defects corresponding to the revascularized
vessel distribution territory in 39/45 (87%) patients in group
B (Table 2). In contrast, only 10/30 patients (33%) treated
with abciximab (group A) displayed transient perfusion
defects (p , 0.001) (Table 2). Scintigraphic images and
regional sestamibi uptake values prior to, during and after
PTRA in a representative patient without abciximab ad-
ministration are illustrated in Figure 1.
Perfusion decreased significantly during PTRA in 3.3 6
2.5 (0 to 10) regions/patient in group B (Table 2). In
contrast, in group A only 1.4 6 2.5 (0 to 6) hypoperfused
regions/patient were observed during PTRA (p , 0.01).
Perfusion in the region with the maximal reduction
during PTRA was 76 6 15% prior to PTRA in group B,
decreased significantly to 56 6 16% (p , 0.001 vs. prior
PTRA) during the procedure and normalized again to 76 6
15 (p , 0.001 vs. during PTRA). In group A, correspond-
ing perfusion values were 76 6 15% at baseline, 67 6 14%
during PTRA (p , 0.001), and 80 6 13 (p , 0.001 vs.
during PTRA) after the procedure. Minimal myocardial
perfusion during PTRA was significantly higher in the
patients receiving abciximab than in the control group
(67 6 14% vs. 56 6 16%, p , 0.01), whereas there was no
significant difference at baseline and at follow-up SPECT
imaging (Table 2).
Myocardial injury. One patient in group B experienced a
procedure-related Q-wave infarction due to prolonged “no
flow” during the procedure and subsequent abrupt vessel
closure several hours following PTRA with a maximal CK
value of 1170 U/l. Immediate reangiography revealed an
occluded left anterior descending artery, and the patient was
successfully treated with repeat PTCA and additional stent-
ing.
As assessed by serial measurements of CK and TrT
values, nine patients (20%) in group B and two patients
(7%) (p 5 0.18) in group A had mild CK and/or TrT
elevations (range: CK, 105 to 203 U/l; TrT, 0.3 to 1.64
ng/ml). Creatine kinase or TrT release could be detected in
9/49 (18%) patients with a perfusion defect and in 2/26
patients (8%) (p 5 0.31) without a perfusion defect. Defect
size in patients with positive enzymes was 4.2 6 2.7 regions,
whereas defect size in patients without elevated enzymes
was 2.3 6 2.5 regions (p , 0.05).
DISCUSSION
Mechanisms of hypoperfusion. Myocardial hypoperfusion
during PTRA may lead to transient myocardial dysfunction
(1,13) and subsequent clinical sequelae including myocardial
enzyme release and non-Q-wave infarctions. Early experi-
mental studies suggested that most ablated particles should
pass through the coronary microcirculation because of their
small size (14). However, in later experiments by Friedman
et al. (15), intracoronary infusion of atheromatous debris
resulted in histologically proven isolated microinfarctions.
Thus, myocardial hypoperfusion may be caused by obstruct-
ing microparticles. Furthermore, Zotz et al. (16) showed
that hypoperfusion may be due to microbubbles obstructing
the capillary bed. Rotation of the burr at 160,000 rpm in
water and in fresh human blood produced bubbles with a
mean size of approximately 90 mm and a short half-life.
Recently, platelet activation and aggregation has been
proposed as another mechanism for transient hypoperfusion
during PTRA, supported by preliminary in vivo and in vitro
experiments (9,17). The number of platelet-monocyte com-
plexes in peripheral blood as markers of platelet activation
increased significantly after rotational atherectomy (17).
Rotation of a burr in vitro in human blood at 180,000 rpm
resulted in platelet aggregates ranging from 20 to 60 mm in
diameter (9). Both lower rotation speed (140,000 rpm) and
addition of the GPIIb/IIIa antagonist abciximab reduced
the number of platelet aggregates significantly. In a recent in
Table 2. Influence of Abciximab on PTRA-Induced Hypoperfusion
Group Incidence Regions preR (%) R (%) postR (%)
A (abciximab) 10/30 (33%)* 1.4 6 2.5† 76 6 15 67 6 14† 80 6 13
B (control) 39/45 (87%) 3.3 6 2.5 76 6 15 56 6 16 76 6 15
Incidence: patients with perfusion defects; Regions: number of regions with significantly reduced perfusion; preR, R, postR:
myocardial perfusion in % of individual maximum before, during and after PTRA.
*p , 0.001 vs. group B; †p , 0.01 vs. group B.
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vitro study, rotablation in human platelet-rich plasma at
150,000 and 180,000 rpm resulted in rapid and extensive
platelet aggregation, which was significantly reduced by
preincubation with abciximab (10).
Our in vivo study further supports the hypothesis that
platelet activation and aggregation is one mechanism lead-
ing to transient hypoperfusion. The platelet GPIIb/IIIa
receptor is part of the final pathway of platelet aggregation.
The reduction of transient ischemia during PTRA by
specific blockade of this receptor provides strong evidence
for the role of platelets in the pathophysiology of transient
hypoperfusion.
However, hypoperfusion was not completely prevented
by GPIIb/IIIa blockade, and other mechanisms like periph-
eral obstruction by ablated particles or microbubbles might
be operative as well and responsible for the remaining effect.
Although previous investigators have shown that the rotat-
ing device produces microbubbles, a causal relationship
between microbubbles and myocardial hypoperfusion has
not been established. The half-life of the bubbles is reported
to be very short ('10 s) (16), and the question arises
whether these microbubbles can result in myocardial hypo-
perfusion that leads to such long-lasting (mean duration of
2.5 h) postprocedural wall-motion abnormalities as de-
scribed by Williams et al. (13). In the latter echocardio-
graphic study, hypoperfusion during balloon inflation in the
PTCA control group resulted in transient wall-motion
abnormalities with a mean recovery time of only 2.7 min.
Myocardial injury. Myocardial injury with release of myo-
cardial enzymes has been described during PTRA and is
probably linked to transient myocardial hypoperfusion. Data
from the Evaluation of 7E3 for the Prevention of Ischemic
Complication (EPIC) trial evaluating the effects of abcix-
imab for the prevention of ischemic complications in per-
cutaneous interventions demonstrated a significant reduc-
tion of non-Q-wave infarctions following directional
atherectomy (7). Recently, a preliminary report (8) demon-
strated a similar reduction of the incidence and magnitude
of CK elevation following PTRA by abciximab.
Concordant with these studies, mild myocardial enzyme
elevations were seen in nine patients (20%) of our control
group, whereas only two patients (7%) in the abciximab group
had enzymatic indices of myocardial injury. Although these
differences did not reach statistical significance (this study was
not designed to detect a significant difference with regard to
clinical end points), these proportions are comparable to the
findings of Braden et al. (8), who reported a 30% incidence of
elevated CK in patients not receiving specific antiplatelet
therapy and a significant reduction to a 17% incidence in
abciximab-treated patients in a series of 326 patients.
Patients with perfusion defects had a higher rate of
enzyme leakage compared to patients without perfusion
defects, but this difference was again (most probably due to
the group size) not statistically significant. The transient
defect size in patients with periprocedural myocardial en-
Figure 1. (A) SPECT images obtained before (preR), during (R)
and 2 days after (postR) PTRA in a patient with a lesion of the left
anterior descending artery (LAD) and a previous inferior myocar-
dial infarction. Sagittal long-axis views are displayed indicating a
transient apical perfusion defect. (B) Polar maps of the left
ventricle of the patient shown in (A). Relative tracer uptake values
in the LAD territory before (preR), during (R) and two days after
(postR) PTRA are depicted. In regions with significantly reduced
perfusion, perfusion values are highlighted. *Region with the
maximal perfusion reduction during the intervention.
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zyme release was significantly larger than in patients with-
out enzymatic signs of myocardial injury.
It can be speculated that transient hypoperfusion during
PTRA occurs rather frequently but leads in only a small
proportion to irreversible myocardial injury. Therefore, the
beneficial effects of abciximab administration on the end
point myocardial perfusion is detectable in an even smaller
sample size than the effect on the end point CK or TrT
release, for which this study was intentionally not designed
and would have needed a significantly larger sample size.
Study limitations. The patients in this prospective but
observational study were not randomized to abciximab or
placebo. However, patients receiving abciximab were re-
cruited consecutively, if no contraindications for abciximab
were present and baseline characteristics between the groups
were balanced. Because the control group was studied earlier
than the treatment group, a learning curve effect due to
improvement in interventional technique and growing op-
erator experience might have influenced the results. How-
ever, this seems to be of minor importance, as periproce-
dural factors did not differ between both groups and two
experienced operators performed all procedures. Analysis of
nuclear images was performed without knowledge of clinical
and/or angiographic data and without knowledge of
periprocedural treatment. Therefore, any bias with regard to
the scintigraphic analysis should be negligible.
We recognize that this study was underpowered to detect
a beneficial effect of GPIIb/IIIa blockade on myocardial
injury and clinical end points. However, we consider myo-
cardial hypoperfusion during rotational atherectomy, for
which we could demonstrate a beneficial effect of abciximab,
as the primary and frequent event leading in some patients
to definitive myocardial injury. This hypothesis is supported
by the finding that myocardial hypoperfusion was signifi-
cantly more extensive in patients with signs of myocardial
injury than in patients without release of myocardial en-
zymes.
For a definitive answer as to whether peri-interventional
GPIIbIIIa blockade reduces clinical events (such as CK or
TrT release) during and after rotational atherectomy, a
larger, randomized and placebo-controlled trial would be
necessary.
Clinical implications. Myocardial hypoperfusion during
PTRA may lead to myocardial dysfunction with transient
wall-motion abnormalities as detected by serial echocardi-
ography during rotational atherectomy (13). In patients
with a high-risk profile due to impaired left ventricular
systolic function. PTRA may lead via the mechanism of
transient hypoperfusion to a further reduction in left ven-
tricular function and subsequent hemodynamic deteriora-
tion. Periprocedural therapy with a GPIIb/IIIa receptor
antagonist could be used in these selected patients to
prevent the potential adverse effects of rotational atherec-
tomy. A similar prophylactic use has been proposed for
intra-aortic balloon counterpulsation during rotational
atherectomy in selected high-risk patients (18).
As has been shown by Abdelmeguid et al. (19) and in the
EPIC study (20), minor CK elevations during coronary
interventions might be associated with a worse long-term
clinical outcome as compared to patients without CK
elevation, although the reasons for this disparity are not
clear yet. Periprocedural therapy with abciximab has been
shown to reduce transient myocardial ischemia and inci-
dence and magnitude of CK elevation and thus might
favorably influence the long-term prognosis.
Conclusions. The results presented here indicate that ad-
ministration of the platelet GPIIb/IIIa receptor antagonist
abciximab reduces incidence, extent and severity of transient
hypoperfusion during PTRA as measured by scintigraphic
perfusion imaging with quantitative tracer uptake analysis.
Thus, platelet activation and aggregation may be one of the
major pathophysiologic mechanisms leading to PTRA-
induced hypoperfusion.
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